157 related articles for article (PubMed ID: 35764368)
1. Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.
Trigos AS; Pasam A; Banks P; Wallace R; Guo C; Keam S; Thorne H; ; Mitchell C; Lade S; Clouston D; Hakansson A; Liu Y; Blyth B; Murphy D; Lawrentschuk N; Bolton D; Moon D; Darcy P; Haupt Y; Williams SG; Castro E; Olmos D; Goode D; Neeson P; Sandhu S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764368
[TBL] [Abstract][Full Text] [Related]
2. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Kaur HB; Vidotto T; Mendes AA; Salles DC; Isaacs WB; Antonarakis ES; Lotan TL
Cancer Immunol Immunother; 2022 Apr; 71(4):943-951. PubMed ID: 34533610
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
van Wilpe S; Simnica D; Slootbeek P; van Ee T; Pamidimarri Naga S; Gorris MAJ; van der Woude LL; Sultan S; Koornstra RHT; van Oort IM; Gerritsen WR; Kroeze LI; Simons M; van Leenders GJLH; Binder M; de Vries IJM; Mehra N
Oncoimmunology; 2022; 11(1):2094133. PubMed ID: 35800157
[TBL] [Abstract][Full Text] [Related]
5. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
6. Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma.
Yang K; Yu W; Liu H; Lou F; Cao S; Wang H; He Z
Cancer Med; 2023 Jul; 12(14):15304-15316. PubMed ID: 37387466
[TBL] [Abstract][Full Text] [Related]
7. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
Kato T; Matsubara N; Shiota M; Eto M; Osawa T; Abe T; Shinohara N; Yasumizu Y; Tanaka N; Oya M; Nishimoto K; Hayashi T; Nakayama M; Kojima T; Namikawa K; Fujisawa T; Okano S; Hida E; Nakamura Y; Bando H; Yoshino T; Nonomura N
BMC Cancer; 2022 Dec; 22(1):1292. PubMed ID: 36494792
[TBL] [Abstract][Full Text] [Related]
8. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
Keam SP; Halse H; Nguyen T; Wang M; Van Kooten Losio N; Mitchell C; Caramia F; Byrne DJ; Haupt S; Ryland G; Darcy PK; Sandhu S; Blombery P; Haupt Y; Williams SG; Neeson PJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581061
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
Front Immunol; 2022; 13():871756. PubMed ID: 35990677
[TBL] [Abstract][Full Text] [Related]
10. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
11. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
13. The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M; Keß P; Nientiedt C; Endris V; Kippenberger M; Leichsenring J; Stögbauer F; Haimes J; Mishkin S; Kudlow B; Kaczorowski A; Zschäbitz S; Volckmar AL; Sültmann H; Jäger D; Duensing A; Schirmacher P; Hohenfellner M; Grüllich C; Stenzinger A; Duensing S
Cancer Immunol Immunother; 2019 Oct; 68(10):1621-1633. PubMed ID: 31549213
[TBL] [Abstract][Full Text] [Related]
14. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A; Gulhan DC; Casado J; Jacobson CA; Nguyen H; Kochupurakkal B; Maliga Z; Yapp C; Chen YA; Schapiro D; Zhou Y; Graham JR; Dezube BJ; Munster P; Santagata S; Garcia E; Rodig S; Lako A; Chowdhury D; Shapiro GI; Matulonis UA; Park PJ; Hautaniemi S; Sorger PK; Swisher EM; D'Andrea AD; Konstantinopoulos PA
Nat Commun; 2020 Mar; 11(1):1459. PubMed ID: 32193378
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
Wu J; Wei Y; Pan J; Jin S; Gu W; Gan H; Zhu Y; Ye DW
Int J Cancer; 2021 Feb; 148(3):673-681. PubMed ID: 33006389
[TBL] [Abstract][Full Text] [Related]
16. Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients.
Liu Y; Jin B; Shen C; Gao X; Qi X; Ma M; Li H; Hao H; Tang Q; Yang K; Mi Y; Guan J; Feng X; He Z; Li H; Yu W
Front Oncol; 2023; 13():1086517. PubMed ID: 37064136
[TBL] [Abstract][Full Text] [Related]
17. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
18. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
19. The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.
Chen J; Tang Y; Liu H; Sun G; Liu H; Zhao J; Wang Z; Zhang Y; Lou F; Cao S; Qin J; Wang H; Liao B; Zeng H
Cancer Med; 2023 Dec; 12(24):22370-22380. PubMed ID: 37986697
[TBL] [Abstract][Full Text] [Related]
20. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
Gong Y; Nagarathinam R; Arisi MF; Gerratana L; Winn JS; Slifker M; Pei J; Cai KQ; Hasse Z; Obeid E; Noriega J; Sebastiano C; Ross E; Alpaugh K; Cristofanilli M; Fernandez SV
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
